KEVZARA
As listed in the register: KEVZARA
200 mg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Sarilumab
- Made by
- Sanofi-Aventis Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (KEVZARA). It describes the substance, not this exact product.
Sarilumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors.
IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, lymphocytes, monocytes, and fibroblasts.
Monoclonal antibodies, including sarilumab, are not eliminated via renal or hepatic pathways.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-02-27
Safety of the active substance
From the US prescribing label for the same active substance (KEVZARA). It describes the substance, not this exact product.
WARNING: RISK OF SERIOUS INFECTIONS Patients treated with KEVZARA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1), Adverse Reactions (6.1) ].
- KEVZARA is contraindicated in patients with known hypersensitivity to sarilumab or any of the inactive ingredients [see Warnings and Precautions (5.5) and Adverse Reactions (6.1) ].
The most common serious adverse reactions were infections.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Sanofi-Aventis Canada Inc |
|---|---|
| Active substance | Sarilumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 200 mg |
| Form | solution |
| Classification | L04AC14 · Cancer treatments and immune-system medicines |
| Route | subcutaneous |
| Dispensing (as stated by the register) | SCHEDULE D · PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02460548 |
| DPD drug code | 94797 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution3 products
- 150 mg
200 mg2
200 mg · 2 companies
- Sanofi-Aventis Canada Inc · this page
- Sanofi-Aventis Canada Inc
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.